MigVax-101
MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Oral |
References
- Jaffe-Hoffman M (11 June 2021). "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. Retrieved 2 November 2021.
- Jaffe-Hoffman M (22 July 2021). "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. Retrieved 2 November 2021.
- "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. Retrieved 2 November 2021.
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.